
    
      The study will evaluate minimum of 2 dose levels of AB680 in 8 participants per cohort.
      Cohorts will be gender-balanced to the extent possible, and will be randomized 3:1, active vs
      placebo, respectively.

      The participants will be closely observed to monitor the general tolerability of AB680.
    
  